Organized Breast and Cervical Cancer Screening: Attendance and Determinants in Rural China
Overview
Public Health
Authors
Affiliations
To evaluate the attendance and determinants of organized cervical and breast cancer (two-cancer) screening, especially higher-level factors, we conducted a cross-sectional survey in central China from June 2018 to November 2019 among 1949 women (age ≥ 35 years). We examined organizer-level factors, provider-level factors, receiver-lever factors and attendance and participation willingness of screening. The results indicate that the attendance and participation willingness of organized two-cancer screening was 61.19% and 77.15%, respectively. After adjustment for potential confounders, women who received screening notification were more likely to have greater participation willingness and higher attendance than those who received no notification (adjusted odds ratio [aOR] = 1.59, 95% confidence interval [CI]: 1.27-1.99; aOR = 98.03, 95% CI: 51.44-186.82, respectively). Compared with being notified about screening by GPs, being notified by community women's leaders and other community leaders were more likely to lead to greater willingness to participate again (aOR = 2.86, 95% CI: 1.13-7.24; aOR = 3.27, 95% CI: 1.26-8.48, respectively) and recommending screening to others (aOR = 2.18, 95% CI: 1.02-4.65; aOR = 4.14, 95% CI: 1.84-9.30, respectively). The results suggest that notification of women about screening by community leaders is an important organizer-level factor. As a part of public health services, the design and implementation of optimal cancer screening strategies may require public-sector involvement at the organizer level instead of a one-man show by the health sector.
Modeling optimal combination of breast and cervical cancer screening strategies in China.
Liu X, Wang Y, Gao B, Lu X, Wang Y, Lu W BMC Womens Health. 2025; 25(1):56.
PMID: 39923068 PMC: 11807319. DOI: 10.1186/s12905-025-03573-x.
Demeke A, Deribe B, Girma M, Gizaw M, Getachew S, Unverzagt S PLoS One. 2025; 20(1):e0315891.
PMID: 39888894 PMC: 11785269. DOI: 10.1371/journal.pone.0315891.
Matovu N, Mugisha N, Jatho A, McShane C Future Oncol. 2024; 20(39):3169-3177.
PMID: 39453024 PMC: 11633408. DOI: 10.1080/14796694.2024.2416885.
The burden of cervical cancer in China.
Shen X, Cheng Y, Ren F, Shi Z Front Oncol. 2022; 12:979809.
PMID: 36203427 PMC: 9530827. DOI: 10.3389/fonc.2022.979809.